2. GPCR/G Protein MAPK/ERK Pathway Apoptosis
  3. Ras Apoptosis
  4. CCG-1423

CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes.

For research use only. We do not sell to patients.

CCG-1423 Chemical Structure

CCG-1423 Chemical Structure

CAS No. : 285986-88-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 73 In-stock
Solution
10 mM * 1 mL in DMSO USD 73 In-stock
Solid
5 mg USD 42 In-stock
10 mg USD 66 In-stock
50 mg USD 211 In-stock
100 mg USD 370 In-stock
200 mg USD 594 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of CCG-1423:

CCG-1423 Related Antibodies

Top Publications Citing Use of Products

View All Ras Isoform Specific Products:

View All Isoforms
K-Ras H-Ras N-Ras Ras

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes[1][2][3].

IC50 & Target

IC50: 1.5 µM (Rho-pathway selective serum response element-luciferase reporter)[1]
In Vitro

CCG-1423 (10 μM; 24 h) affects invasion by cultured PC-3 cells into a Matrigel matrix and inhibits 54% mitochondrial metabolism of WST-1[1].
? CCG-1423 (0-100 μM; 24 h) inhibits RhoA and RhoC signaling pathways with an IC50 value of 1.5 μM for Rho-pathway selective serum response element-luciferase reporter[1].
? CCG-1423 (1 μM; 16 h) improves glucose uptake in both L6 cells and primary human myotubes[2].
? CCG-1423 (10 μM; 18-19 h) inhibits expression of Rho downstream[2].
? CCG-1423 (3 μM; 25 h) selectively stimulates apoptosis of RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CCG-1423 Related Antibodies

Cell Invasion Assay[1]

Cell Line: PC-3 cell line
Concentration: 10 µM
Incubation Time: 24 hours
Result: Inhibited 71% invasion by cultured PC-3 cells into a Matrigel matrix.

Western Blot Analysis[2]

Cell Line: L6 myotubes
Concentration: 1 µM
Incubation Time: 48 hours
Result: Increased insulin-stimulated Akt phosphorylation, blocked ERK phosphorylation, and increased IRS-1 tyrosine phosphorylation and its association with the p85 regulatory subunit of PI3K.

Cell Proliferation Assay[3]

Cell Line: PC-3 cell line
Concentration: 0.3 µM
Incubation Time: 8 days
Result: Inhibited growth of PC-3 prostate cancer cells with an IC50 value of 1 µM with 30 µM LPA adding.

Apoptosis Analysis[3]

Cell Line: RhoC-overexpressing A375M2 and low RhoC-expressing A375 melanoma cell lines
Concentration: 3 µM
Incubation Time: 25 hours
Result: Stimulated apoptosis of A375M2 cell line compared with the parental cell line.
In Vivo

CCG-1423 (0.15 mg/kg; i.p. once daily for two weeks) affects glucose tolerance and insulin levels in HFD-fed mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 16-week-old mice with HFD-induced obesity[1]
Dosage: 0.15 mg/kg
Administration: Intraperitoneal injection; 0.15 mg/kg once per day; for two weeks
Result: Improved glucose tolerance and reduced insulin levels at 30 minutes after glucose injection.
Molecular Weight

454.75

Formula

C18H13ClF6N2O3
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(NOC(C)C(NC1=CC=C(Cl)C=C1)=O)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (219.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1990 mL 10.9951 mL 21.9901 mL
5 mM 0.4398 mL 2.1990 mL 4.3980 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.94%

COA (246 KB) LCMS (111 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1990 mL 10.9951 mL 21.9901 mL 54.9753 mL
5 mM 0.4398 mL 2.1990 mL 4.3980 mL 10.9951 mL
10 mM 0.2199 mL 1.0995 mL 2.1990 mL 5.4975 mL
15 mM 0.1466 mL 0.7330 mL 1.4660 mL 3.6650 mL
20 mM 0.1100 mL 0.5498 mL 1.0995 mL 2.7488 mL
25 mM 0.0880 mL 0.4398 mL 0.8796 mL 2.1990 mL
30 mM 0.0733 mL 0.3665 mL 0.7330 mL 1.8325 mL
40 mM 0.0550 mL 0.2749 mL 0.5498 mL 1.3744 mL
50 mM 0.0440 mL 0.2199 mL 0.4398 mL 1.0995 mL
60 mM 0.0367 mL 0.1833 mL 0.3665 mL 0.9163 mL
80 mM 0.0275 mL 0.1374 mL 0.2749 mL 0.6872 mL
100 mM 0.0220 mL 0.1100 mL 0.2199 mL 0.5498 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CCG-1423 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CCG-1423285986-88-1CCG1423CCG 1423RasApoptosismetastasisprostate,serumconformational restrictionbioisostereglucose tolerancePC-3miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CCG-1423
Cat. No.:
HY-13991
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.